author-photo

Jeremy Barton

Seattle University

13

Papers

610

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

Origins of Amyloid Oligomers and Novel Approaches for their Detection

2020
- Jeremy Barton
Show All
- Source
- Cite
- Save
Citations (0)
The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients

2019 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (350)
A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable colorectal cancer (MSS CRC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Anticancer drugs do benefit patients

2017
- Jeremy Barton
- Jane Salsbury
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies

2008 Blood
Show All
- Source
- Cite
- Save
Citations (181)
refractory or recurrent CD30+ hematologic malignancies

2007
Show All
- Source
- Cite
- Save
Citations (0)
Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

2006 Blood
Show All
- Source
- Cite
- Save
Citations (9)
SGN-30 (Anti-CD30 mAb) Has a Single-Agent Response Rate of 21% in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).

2006 Blood
Show All
- Source
- Cite
- Save
Citations (13)
SGN-30 (Anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL)

2005 Blood
Show All
- Source
- Cite
- Save
Citations (13)
Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL).

2005 Blood
Show All
- Source
- Cite
- Save
Citations (4)